Free Trial
NYSE:PEN

Penumbra (PEN) Stock Price, News & Analysis

Penumbra logo
$244.12 -0.03 (-0.01%)
(As of 11/29/2024 ET)

About Penumbra Stock (NYSE:PEN)

Key Stats

Today's Range
$242.30
$246.61
50-Day Range
$186.89
$248.96
52-Week Range
$148.00
$277.34
Volume
114,677 shs
Average Volume
329,187 shs
Market Capitalization
$9.37 billion
P/E Ratio
283.86
Dividend Yield
N/A
Price Target
$230.92
Consensus Rating
Moderate Buy

Company Overview

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
87th Percentile Overall Score

PEN MarketRank™: 

Penumbra scored higher than 87% of companies evaluated by MarketBeat, and ranked 172nd out of 964 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Penumbra has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Penumbra has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Penumbra's stock forecast and price target.
  • Earnings Growth

    Earnings for Penumbra are expected to grow by 37.37% in the coming year, from $2.81 to $3.86 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Penumbra is 283.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.81.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Penumbra is 283.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 109.89.

  • Price to Earnings Growth Ratio

    Penumbra has a PEG Ratio of 2.46. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Penumbra has a P/B Ratio of 8.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Penumbra's valuation and earnings.
  • Percentage of Shares Shorted

    5.00% of the outstanding shares of Penumbra have been sold short.
  • Short Interest Ratio / Days to Cover

    Penumbra has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Penumbra has recently decreased by 15.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Penumbra does not currently pay a dividend.

  • Dividend Growth

    Penumbra does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.00% of the outstanding shares of Penumbra have been sold short.
  • Short Interest Ratio / Days to Cover

    Penumbra has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Penumbra has recently decreased by 15.04%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Penumbra has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for Penumbra this week, compared to 8 articles on an average week.
  • Search Interest

    Only 4 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Penumbra to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,166,574.00 in company stock.

  • Percentage Held by Insiders

    Only 5.00% of the stock of Penumbra is held by insiders.

  • Percentage Held by Institutions

    88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Penumbra's insider trading history.
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

Black Friday: 59% dividend from Bitcoin (No Crypto Needed)
Get a 59% Dividend from Bitcoin—No Crypto Required! Our Black Friday special reveals the "Bitcoin Income Vault," a strategy that lets you collect dividends from Bitcoin - without buying a single coin or trade options. Start with as little as $50 and have the chance to enjoy almost monthly payouts.
BTIG Research Issues Positive Forecast for Penumbra (NYSE:PEN) Stock Price
Leerink Partners Sticks to Their Buy Rating for Penumbra (PEN)
FY2024 EPS Estimates for Penumbra Boosted by Leerink Partnrs
Penumbra price target raised to $270 from $232 at BTIG
See More Headlines

PEN Stock Analysis - Frequently Asked Questions

Penumbra's stock was trading at $251.54 on January 1st, 2024. Since then, PEN shares have decreased by 2.9% and is now trading at $244.12.
View the best growth stocks for 2024 here
.

Penumbra, Inc. (NYSE:PEN) issued its quarterly earnings data on Wednesday, October, 30th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.16. The business's revenue was up 11.1% compared to the same quarter last year.

Penumbra's Board of Directors approved a share buyback program on Tuesday, August 13th 2024, which permits the company to buy back $200,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 2.6% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board of directors believes its stock is undervalued.

Top institutional shareholders of Penumbra include FMR LLC (15.36%), Champlain Investment Partners LLC (4.03%), State Street Corp (3.22%) and RTW Investments LP (2.07%). Insiders that own company stock include Adam Elsesser, Arani Bose, Johanna Roberts, Harpreet Grewal, Bridget O'rourke, Surbhi Sarna, Don W Kassing and Thomas Wilder.
View institutional ownership trends
.

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Penumbra investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW), Adobe (ADBE) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
10/30/2024
Today
11/30/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/27/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Employees
4,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$230.92
High Stock Price Target
$270.00
Low Stock Price Target
$150.00
Potential Upside/Downside
-5.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
14 Analysts

Profitability

Net Income
$90.95 million
Pretax Margin
1.26%

Debt

Sales & Book Value

Annual Sales
$1.16 billion
Cash Flow
$2.83 per share
Book Value
$28.77 per share

Miscellaneous

Free Float
36,460,000
Market Cap
$9.37 billion
Optionable
Optionable
Beta
0.51

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NYSE:PEN) was last updated on 12/1/2024 by MarketBeat.com Staff
From Our Partners